BenevolentAI SA
AEX:BAI
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| UK |
|
BenevolentAI SA
AEX:BAI
|
11.6m EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
295.7B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.1B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
248.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
309B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.1B USD |
Loading...
|
Market Distribution
| Min | -1 510% |
| 30th Percentile | 0.4% |
| Median | 0.5% |
| 70th Percentile | 0.7% |
| Max | 7 323.1% |
Other Profitability Ratios
BenevolentAI SA
Glance View
BenevolentAI SA is a holding company that engages in the research and development and sale of AI-enabled drugs. The firm through the combined capabilities of its AI platform, scientific ability and wet-lab facilities deliver new drug candidates with a higher probability of clinical success than those developed using traditional methods. The company has an array of scientifically validated discoveries. The Company, through its BenevolentAI Platform, offers in-house pipeline of over 20 disease programs, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies, such as AstraZeneca, as well as other research and charitable institutions.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for BenevolentAI SA is -14.7%, which is in line with its 3-year median of -14.7%.
Over the last 0 months, BenevolentAI SA’s Gross Margin has decreased from -14.7% to -14.7%. During this period, it reached a low of -14.7% on Jul 30, 2024 and a high of -14.7% on Jul 30, 2024.
